Literature DB >> 16472206

Has the amyloid cascade hypothesis for Alzheimer's disease been proved?

John Hardy1.   

Abstract

After much initial debate for and against the role of amyloid in Alzheimer's disease (AD), mutations on the amyloid precursor protein (APP) and processing pathways that increase levels of the amyloid b peptide of 42 residues (Abeta42) have established that faulty function or processing of these proteins are responsible for AD pathogenesis. Given the neurotoxicity of aggregates of Ab42, the central role of this peptide in AD pathogenesis is self evident. In this article, I summarize the major pieces of evidence adduced to support the amyloid cascade hypothesis and point out their limitations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16472206     DOI: 10.2174/156720506775697098

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  85 in total

1.  Value in development of a TAPIR-like mouse monoclonal antibody to Abeta.

Authors:  Kumar Sambamurti; Miguel A Pappolla; K S Jagannatha Rao
Journal:  J Alzheimers Dis       Date:  2008-06       Impact factor: 4.472

2.  Longitudinal change in working memory as a function of APOE genotype in midlife and old age.

Authors:  Pamela M Greenwood; Thomas Espeseth; Ming-Kuan Lin; Ivar Reinvang; Raja Parasuraman
Journal:  Scand J Psychol       Date:  2014-06

3.  Variation in RTN3 and PPIL2 genes does not influence platelet membrane beta-secretase activity or susceptibility to alzheimer's disease in the northern Irish population.

Authors:  Robyn Carson; Amy Jayne McKnight; Stephen Todd; Wei Wei Liu; Shirley Heggarty; David Craig; Bernadette McGuinness; G Brent Irvine; A Peter Passmore; Janet A Johnston
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

4.  Progress in the development of new drugs in Alzheimer's disease.

Authors:  Antoine Piau; F Nourhashémi; C Hein; C Caillaud; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-01       Impact factor: 4.075

Review 5.  Alzheimer disease therapy--moving from amyloid-β to tau.

Authors:  Ezio Giacobini; Gabriel Gold
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

6.  Amyloid-beta expression in retrosplenial cortex of triple transgenic mice: relationship to cholinergic axonal afferents from medial septum.

Authors:  R T Robertson; J Baratta; J Yu; F M LaFerla
Journal:  Neuroscience       Date:  2009-09-20       Impact factor: 3.590

7.  Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Authors:  Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

Review 8.  Omega-3 fatty acids: potential role in the management of early Alzheimer's disease.

Authors:  Gregory A Jicha; William R Markesbery
Journal:  Clin Interv Aging       Date:  2010-04-07       Impact factor: 4.458

9.  Angiotensins and Alzheimer's disease: a bench to bedside overview.

Authors:  Patrick G Kehoe
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

10.  Intrathecal corticosteroids might slow Alzheimer's disease progression.

Authors:  Joseph Martin Alisky
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.